Open AccessExpression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer
Author(s) -
Kei Ito,
Hiroyasu Ogata,
Naoko Honma,
Kazutoshi Shibuya,
Tetsuo Mikami
Publication year - 2019
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000503311
Subject(s) - triple negative breast cancer , pi3k/akt/mtor pathway , cancer research , estrogen receptor , glut3 , rptor , cell growth , biology , signal transduction , chemistry , breast cancer , cancer , glut1 , medicine , microbiology and biotechnology , endocrinology , glucose transporter , biochemistry , insulin
Triple-negative breast cancer (TNBC), which lacks expression of estrogen receptor (ER), progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2), currently has no effective hormonal or molecular target therapy.